Inorganic arsenic trioxide (As 2 O 3 ) is a highly effective treatment for acute promyelocytic leukemia (APL). However, other cancers do not respond well to this form of arsenic at clinically achievable doses. We tested a novel arsenical, S-dimethylarsino-glutathione (darinaparsin) for efficacy in various malignancies in vitro. Darinaparsin is significantly more potent than As 2 O 3 at mediating apoptosis in various malignant cell lines and is highly active against APL cells derived for As 2 O 3 resistance. We provide evidence that darinaparsin triggers apoptosis by inducing signaling pathways that do not completely overlap with As 2 O 3 . We show that darinaparsin induces apoptosis and oxidative stress to a greater extent than As 2 O 3 , although like As 2 O 3 , darinaparsin-induced toxicity is c-Jun NH 2 -terminal kinase-dependent. However, darinaparsin does not induce promyelocytic leukemia/retinoic acid receptor a (PML/ RARa) degradation or rearrange PML nuclear bodies in APL cells, nor is its toxicity increased by glutathione depletion. Darinaparsin treatment results in higher intracellular arsenic accumulation when compared to As 2 O 3 treatment. This may be explained by our finding that As 2 O 3 , but not darinaparsin, is efficiently exported by ABCC1, suggesting increased therapeutic efficacy of darinaparsin in ABCC1-overexpressing tumors. Our studies indicate that darinaparsin efficiently kills tumor cells with increased antioxidant capacity and drug exporters and suggest that darinaparsin may have a broader therapeutic spectrum than As 2 O 3 .
Introduction
Arsenic is known as an environmental toxicant affecting the lives of millions of people all around the world, but is also an anticancer agent. Arsenic trioxide (As 2 O 3 ) is a proven effective salvage treatment for patients with acute promyelocytic leukemia (APL) who have relapsed after all trans retinoic acid (ATRA) treatment. 1 The therapeutic use of As 2 O 3 in APL has recently advanced to first-line therapy, where several reports have described benefit. [2] [3] [4] The activity of As 2 O 3 in APL is, in part, related to the disappearance of the promyelocytic leukemia (PML)/retinoic acid receptor (RAR)a fusion protein, the gene product of the chromosomal translocation t(15,17) characteristic of APL, and the induction of differentiation. 5, 6 In addition, As 2 O 3 deregulates numerous proteins through binding to sulfhydryl groups, 7 inhibits mitochondrial respiratory function 8 and induces Bax oligomerization, 9 triggering apoptosis in non-APL cell lines. Considerable evidence suggests that As 2 O 3 induces the generation of reactive oxygen species (ROS). In fact, the glutathione (GSH) redox system is known to affect the activity of arsenicals. 10 Cells expressing higher levels of GSH or GSHassociated enzymes 11 are less sensitive to As 2 O 3 than cells expressing lower levels of these molecules. 11, 12 GSH depletion by buthionine sulfoximine (BSO) significantly enhances As 2 O 3 -induced apoptosis. 10, 13 Different signaling pathways have been implicated as mediators of the cytotoxic effects of As 2 O 3. Using pharmacologic and genetic approaches, we and others demonstrated that c-Jun NH 2 -terminal kinase (JNK) activation is required for As 2 O 3 -induced apoptosis in several malignant cell lines, including the APL cell line NB4. 14, 15 As 2 O 3 has been investigated in the treatment of non-APL malignancies. 16, 17, 18 However, most of these studies showed substantially reduced antitumor effects of clinically achievable levels of As 2 O 3 , compared with those seen in APL. This has led to a search for other elemental arsenic-containing compounds with improved efficacy in less sensitive cancers. Although other arsenic analogues have been reported to induce apoptosis efficiently, concentrations were not used at clinically relevant doses. There has also been recent interest in arsenic's biotransformation products, specifically its methylated intermediates, some of which have been proven to be more potent growth inhibitors and apoptotic inducers than iAs III . 19 These findings raised the possibility that various forms of arsenicals could be investigated as novel anticancer agents.
Although initial clinical trials in both APL and myeloma have suggested that melarsoprol results in greater dose-limiting toxicities than As 2 O 3 , it is generally accepted that organic arsenicals are less toxic than inorganic arsenicals. 20 Therefore, darinaparsin (S-dimethylarsino-glutathione; ZIO-101) was synthesized by conjugating dimethylarsenic to glutathione. Consistent with the predicted lower toxicity, the LD 50 of darinaparsin is about 50-fold higher than As 2 O 3 in mice 21 although there is evidence of significant activity against multiple cancers in vitro. Darinaparsin is currently in phase I studies in both hematologic malignancies and solid tumors, although the mechanism of the antitumor effects has not been elucidated.
In the present study, we report that darinaparsin is significantly more potent than As 2 O 3 at inducing growth arrest and apoptosis in various hematologic malignancies in vitro. We show that darinaparsin induces apoptosis and oxidative stress to a greater extent than As 2 O 3 . We provide evidence that darinaparsin triggers apoptosis by inducing signaling pathways that do not completely overlap with the ones induced by As 2 O 3 .
These findings suggest that arsenic's configuration plays a key role in its ability to induce apoptosis of malignant cells, and that this characteristic can be used to develop more efficient anticancer drugs for the treatment of other hematologic malignancies.
Materials and methods

Cells culture
All cells were grown in a humidified chamber at 37 1C with 5% CO 2 . NB4 (provided by Dr M Lanotte), 22 NB4-M-AsR2 arsenicresistant NB4 subclones (AR2; derived in our lab 13 ), IM9 and CCRF-CEM (American Type Culture Collection, Manassas, VA, USA) cells were cultured in RPMI-1640 media (Wisent, St-Bruno, Quebec, Canada) supplemented with 10% fetal bovine serum (FBS; Wisent) and penicillin/streptomycin (Wisent). AR2 cells were also maintained in 2 mM As 2 O 3 (Sigma, Oakville, Ontario, Canada). In experiments using AR2 cells, cells were washed and allowed to grow in the absence of As 2 O 3 for 24 h before replating with the indicated treatments. SEK1
and SEK1
À/À mouse embryonic fibroblast (MEF) cell lines (courtesy of Dr Jim Woodgett, University of Toronto, Ontario, Canada) were cultured in Dulbecco's modified Eagle's medium media (Wisent) supplemented with 10% FBS and penicillin/ streptomycin.
PML/RARa immunoblotting
Western blots for the detection of PML/RARa were performed as we have previously described. 13 Briefly, cell extracts were made and proteins were electrophoresed and transferred to nitrocellulose membranes (Bio-Rad, Mississauga, Ontario, Canada). Membranes were blocked and then hybridized with an antibody against RARa (1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA) followed by rabbit secondary antibody. Bands were visualized using Immobilion (Millipore, Billerica, MA, USA). Immunostaining for b-actin was used to confirm equal protein loading.
PML bodies
NB4 cells were treated for 12 h with either 1 mM As 2 O 3 or darinaparsin, washed twice, and spread on glass slides. Slides were fixed with 4% paraformaldehyde, washed in phosphatebuffered saline (PBS), permeabilized with 0.2% Triton X-100, blocked in 2% FBS in PBS and stained with mouse anti-PML antibody 24 (5E10; 1:10; antibody from Dr R van Driel with technical assistance by the laboratory of Dr Kathy Borden, University of Montreal) in blocking solution for 2 h. Slides were washed three times in 1 Â PBS (pH 7.4), and stained with fluorescein isothiocyanate (FITC)-conjugated, anti-mouse antibody (1:100; Jackson Immunoresearch Laboratories, West Grove, PA, USA) for 45 min. After secondary antibody incubation, slides were washed and coverslips mounted in Vectashield supplemented with 4 0 ,6-diamidino-2-phenylindole (DAPI; Vector Laboratories Inc., Burlington, Ontario, Canada), and sealed. Fluorescence was observed using Â 100 optical magnification on an inverted laser scanning confocal microscope (LSM510 META; Carl Zeiss MicroImaging Inc., Toronto, Ontario, Canada). All channels were detected separately, and no cross talk between the channels was observed. The confocal micrographs represent a single optical section through the plane of the cell. Images were obtained using LSM510 software (Carl Zeiss MicroImaging, Inc.) and were displayed using Photoshop CS 8.0 (Adobe, Etobicoke, Ontario, Canada).
JNK kinase assay
The JNK kinase assay was performed as described. 15 
Protein carbonyls
NB4 and AR2 cells were treated for 48 h with As 2 O 3 or darinaparsin and extracts used to determine protein carbonylation following a colorimetric carbonyl assay as previously described. 25 hABCC1 qPCR cDNA was generated from RNA using random primers and Superscript II reverse transcriptase (Invitrogen). ABCC1 gene expression was determined using Power SYBR green master mix (Applied Biosystems, Foster City, CA, USA) with the following primer set designed using the Primer Express 3.0 (Applied Biosystems): 5 0 -GGGACTCAGGAGCACACGAA-3 0 and 5 0 -AAA TGCCCAGGGCTCCAT-3 0 . GAPDH) was used as the endogenous control using a VIC-labeled Taqman probe and Taqman Fast Master Mix (Applied Biosystems). Quantiative PCR (qPCR) was performed on the 7500 Fast Real-time PCR system using standard parameters and analyzed using relative quantification with NB4 cells as the calibrator.
Atomic absorption spectrometry
Cells were treated with various concentrations of As 2 O 3 or darinaparsin for 24 h. Viable cells were counted using the Trypan blue exclusion method and 6 Â 10 6 cells were used for each treatment to prepare cellular extracts using protease and phosphatase-free radioimmuno-precipitation assay buffer. Standards were prepared using 100 mg/ml arsenic in 5% HNO 3 Instra-Analyzed standard (JT Baker, Phillipsburg, NJ, USA). Arsenic quantitation was performed by flow injection hydride analysis followed by atomic absorption spectroscopy on a PerkinElmer Analyst 100 Atomic Absorption Spectrometer (PerkinElmer, Waltham, MA, USA).
Statistical analysis
All statistical tests aiming at evaluating significance were determined by analysis of variance (one-way analysis of variance) followed by Newman-Keuls post-tests using Prism version 3.0 (GraphPad software, San Diego, CA, USA).
Results
Darinaparsin is a more potent inducer of growth arrest and apoptosis than As 2 O 3 in various hematologic malignancies in vitro
We first examined the effects of the organic arsenical darinaparsin in different malignant hematologic cell lines. When the APL cell line NB4, which is highly sensitive to As 2 O 3 -induced apoptosis, was treated for 48 h, both As 2 O 3 and darinaparsin significantly suppressed cell growth ( Figure 1a , upper left), although darinaparsin was a more potent inducer of growth arrest. This difference was supported by showing that darinaparsin induced more apoptosis ( Figure 1b , upper left) and caspase 3 activation (Figure 1c , upper left) in these cells than As 2 O 3 . We also tested the effects of darinaparsin on a As 2 O 3 -resistant subclone of NB4 cells (AR2), which has an IC 50 value for As 2 O 3 that is roughly 10 times higher than its parental NB4 cell line. 13 As expected, the As 2 O 3 concentrations used did not induce growth arrest or apoptosis, but darinaparsin concentrations as low as 0.5 and 1.0 mM induced significant growth inhibition, apoptosis and caspase 3 cleavage in these cells (Figures 1a-c, upper right). These results were confirmed in the independently derived As 2 O 3 -resistant NB4 cell clone, AR3 (data not shown). Thus, our results demonstrate that darinaparsin exhibits no cross-resistance with As 2 O 3 in these cellular models.
We next tested darinaparsin in IM9 B lymphoblastoid cells and acute lymphoblastic leukemia CCRF-CEM cells, which are both less sensitive to As 2 O 3 than NB4 cells. As shown in Figures 1a-c (lower panels), darinaparsin induced significantly more growth inhibition, apoptosis and caspase 3 activation than As 2 O 3 at equimolar concentrations in these cell lines. Importantly, at equimolar concentrations, As 2 O 3 provides twice as much elemental arsenic as darinaparsin, further supporting the enhanced cytotoxicity of darinaparsin compared to As 2 O 3 . These results, especially the induction of apoptosis by darinaparsin in As 2 O 3 -resistant cells, suggest that darinaparsin may utilize alternative signaling pathways leading to apoptosis.
Darinaparsin does not induce PML/RARa degradation in NB4 cells
The unique sensitivity of NB4 cells to As 2 O 3 -mediated cytotoxicity has been associated with PML/RARa degradation. We have previously published that 1 mM As 2 O 3 degrades PML/RARa and mediates the reappearance of wild-type PMLcontaining nuclear bodies in these cells. 26 Using western blotting, we determined that darinaparsin treatment does not degrade PML/RARa in NB4 cells. Expression of PML/RARa was completely lost after treatment with As 2 O 3 in NB4 cells (Figure 2a, lanes 2, 3 and 4) , whereas PML/RARa expression remained unchanged after darinaparsin treatment (Figure 2a , lanes 5, 6 and 7) at concentrations that clearly induced growth inhibition and apoptosis in this cell line (Figure 1 upper left panels).
In APL, PML/RARa disrupts formation of wild-type PML nuclear bodies, which are restored upon treatment with As 2 O 3 . In order to confirm the western blot results, we assessed PML staining by immunofluorescence in NB4 cells treated for 12 h with 1 mM As 2 O 3 or darinaparsin. Cells were stained with anti-PML antibodies ( Figure 2b ) and counterstained with DAPI to confirm nuclear staining (data not shown). We see that, as expected, As 2 O 3 treatment causes larger PML nuclear bodies to form when compared to the microparticulate pattern of NB4 cells. Darinaparsin did not alter the microparticulate pattern of PML staining, confirming that PML/RARa degradation does not occur and is not necessary for apoptosis induced by darinaparsin.
Darinaparsin induces more cellular oxidative stress than As 2 O 3
Oxidative damage has been postulated to be a key mechanism by which arsenic initiates the apoptotic process. Because darinaparsin is a more potent inducer of apoptosis than As 2 (Figure 4b ).
To document oxidative damage to cellular components, we analyzed proteins isolated from NB4 and AR2 cells treated with As 2 O 3 or darinaparsin for 48 h. Proteins carbonyls are generated by a variety of mechanisms and are sensitive indices of oxidative injury. 27 Figure 3c shows that oxidative damage to proteins was significantly higher in both cell lines when treated with darinaparsin than with As 2 O 3 . Similar results were obtained in IM9 cells (data not shown). At the concentrations tested, we did not see significant ROS induced by As 2 O 3 and yet oxidative damage was observed. Therefore, we tested the amount of mitochondrial O 2 KÀ formation as a more sensitive measure of ROS production using the fluorescent dye, MitoSoxRed. Indeed, As 2 O 3 induces significant mitochondrial O 2 KÀ formation, whereas darinaparsin induces significantly more (Figure 3d ). These data suggest that ROS generation and oxidative damage Differential effects of general oxidants and glutathione modulators on As 2 O 3 and darinaparsin
In order to further evaluate the role of reactive species in darinaparsin-mediated apoptosis, we assessed the effects of two Darinaparsin is more potent than As 2 O 3 in vitro Z Diaz et al redox active compounds, ascorbic acid (AA) and trolox, on darinaparsin cytotoxicity. These compounds are widely heralded as antioxidants, 28, 29 but can also act as oxidizing agents in the presence of As 2 O 3 .
10,25 Therefore, we asked whether the synergy observed between AA or trolox and As 2 O 3 could also occur with darinaparsin. Figures 4a and b show that AA and trolox increase As 2 O 3 -mediated apoptosis, consistent with previous reports. 10, 25 However, both compounds significantly protected NB4 cells from darinaparsin-mediated toxicity, suggesting that the redox-cycling properties of the two arseniccontaining compounds differ.
In addition, GSH and GSH regulation are implicated in the response to As 2 O 3 . Therefore, we used N-acetyl-L-cysteine (NAC) and BSO to modulate intracellular GSH levels. NAC, a thiol-containing antioxidant, is a precursor of reduced glutathione 30 that can stimulate GSH synthesis and enhance GST activity. NAC is also considered to be a ROS scavenger, due to its reactivity toward ROS, H 2 O 2 and OH K . As shown in Figure 4c , NAC protects NB4 cells from either As 2 O 3 or darinaparsin-induced cell death. BSO depletes GSH by inhibiting g-glutamyl-cysteine synthetase, a rate-limiting enzyme of GSH synthesis 31, 32 and sensitizes a wide variety of malignant cells to As 2 O 3 toxicity. 13 Although GSH depletion by nontoxic doses of BSO could significantly increase As 2 O 3 sensitivity, the cytotoxicity of darinaparsin was not modified by decreased intracellular GSH levels (Figure 4d ).
JNK activation mediates apoptosis induced by both As 2 O 3 and darinaparsin
We have reported that JNK activation is necessary for As 2 O 3 -induced apoptosis of NB4 cells. 15 Therefore, we asked whether the activation of JNK might play a role in darinaparsin-mediated apoptosis in NB4 cells. First, we assessed JNK activation using an immune complex assay with GST-c-jun as an exogenous substrate. We observed that 1 and 2 mM darinaparsin for 16 h induced significant JNK activation leading to phosphorylation of c-jun. When compared with equimolar concentrations of As 2 O 3 , we observed that darinaparsin triggered more JNK activity than As 2 O 3 . Consistent with the idea that darinaparsin increases oxidative stress, NAC blocks JNK activation by both As 2 O 3 and darinaparsin in NB4 cells (Figures 5a and b) .
In order to investigate whether JNK activation is necessary for darinaparsin-induced apoptosis, we examined the effects of pharmacologic inhibition of JNK on As 2 O 3 and darinaparsin signaling in NB4 cells. The JNK inhibitor SP600125 has previously been shown to markedly inhibit JNK activation by various agents. 33 A 48-h treatment of NB4 cells with 5 mM SP600125 inhibits the As 2 O 3 -mediated induction of c-jun expression, which is JNK-dependent (data not shown), demonstrating that 5 mM is an effective inhibitory dose. We treated NB4 cells with the combination of As 2 O 3 or darinaparsin (0.5 and 1 mM) and SP600125 (5 mM) to determine whether inhibition of JNK activity repressed As 2 O 3 or darinaparsin-induced growth Darinaparsin is more potent than As 2 O 3 in vitro Z Diaz et al inhibition. After 3 days of treatment, SP600125 significantly protected cells from growth inhibition by either As 2 O 3 or darinaparsin, whereas SP600125 alone had little effect on cell growth (Figure 5d ). To confirm our findings using biochemical inhibitors, we obtained cells with a genetic defect in SEK1, an upstream activator of JNK. Although SEK1 À/À cells continue to express normal JNK protein levels (data not shown), the activation of this pathway in response to multiple inducers, including As 2 O 3 15 is markedly reduced. We determined whether the reduced JNK response of SEK1 À/À cells was associated with resistance to darinaparsin-induced apoptosis. 48 h treatment with up to 3.5 mM As 2 O 3 or darinaparsin led to a dose-dependent decrease in viable wild-type MEFs, but no signficant growth inhibition by either agent in the SEK1 À/À MEFs (Figures 5e and f) . A propidium iodide assay confirmed the induction of apoptosis by both agents in the wild-type MEFs but not in SEK1 À/À MEFs (data not shown). All together, these data suggest that JNK-related signalling pathways are important for both darinaparsin and As 2 O 3 -mediated apoptosis. murine embryo fibroblasts were treated with As 2 O 3 (e) or darinaparsin (f). Cell viability was evaluated using Trypan blue exclusion on days 1, 3 and 6. These data represent three independent experiments. Asterisks indicate significant differences from As 2 O 3 -treated cells (*Po0.05; **Po0.01; ***Po0.001).
Darinaparsin is more potent than As 2 O 3 in vitro Z Diaz et al Differences in cellular transport of arsenicals may determine darinaparsin and As 2 O 3 cytotoxicity
One potential factor to account for the different degrees of response to As 2 O 3 and darinaparsin is cellular uptake and export. Therefore, we measured the intracellular levels of inorganic arsenic in NB4 cells after treatment with either compound for 24 h using atomic absorption spectroscopy. As shown in Figure 6 , the intracellular concentrations of inorganic arsenic were somewhat less when NB4 cells were treated with 1 mM darinaparsin, as compared to 1 mM As 2 O 3 (14.50 vs 17.16 ppb). However, it is important to note that a 1 mM concentration of As 2 O 3 provides 2 mM elemental arsenic, whereas 1 mM darinaparsin contains 1 mM elemental arsenic. Therefore, when comparing equal amounts of elemental arsenic (that is comparing 0.5 mM As 2 O 3 with 1 mM darinaparsin), we observed that NB4 cells accumulate substantially more inorganic arsenic when treated with darinaparsin. Treatment with As 2 O 3 leads to the accumulation of 60% less arsenic in the As 2 O 3 -resistant AR2 cells than in the parental NB4 cells. This may be one mechanism of resistance in these cells. However, when AR2 cells were treated with darinaparsin, we observed a higher arsenic concentration than with As 2 O 3 (13.09 vs 7.47 ppb), which equals the concentration seen after darinaparsin treatment of NB4 cells. Taking into account the 2:1 ratio of elemental arsenic in equimolar As 2 O 3 vs darinaparsin, this suggests that darinaparsin is either four times more efficiently absorbed or four times less efficiently effluxed than As 2 O 3 .
ABCC1 (Mrp1) is known to be involved in the transport of and resistance to arsenic. 34 We hypothesized expression of more ABCC1 may explain the decreased intracellular arsenic levels seen in these cells. Indeed, we found that AR2 cells express approximately eight times more ABCC1 mRNA than NB4 cells (Figure 7) , as assessed by qPCR. To address the importance of ABCC1 overexpression to the resistance of AR2 cells, we used an ABCC1 inhibitor, MK571, to determine if decreasing ABCC1 activity would sensitize these cells to As 2 O 3 . When AR2 cells were treated for 48 h with 5 mM MK571 in addition to the 2 mM arsenic concentration (Figure 7c ) confirming this concentration of MK571 effectively inhibited export. Interestingly, MK571 cotreatment did not alter darinaparsin-induced apoptosis suggesting that, unlike As 2 O 3 , darinaparsin may be an effective treatment in tumors that overexpress ABCC1.
Discussion
As 2 O 3 is used to treat APL patients with great success, but has restricted use in other malignancies because of the dose-limiting toxicities. Here, we have found that a novel arsenic-containing compound, darinaparsin, was significantly more cytotoxic than As 2 O 3 in several hematologic malignancies in vitro.
In addition, the As 2 O 3 -resistant AR2 cells were as sensitive to darinaparsin as the As 2 O 3 -sensitive parental cells, showing no cross-resistance with As 2 O 3 . We find that the two compounds share some similarities in their signaling mechanisms, such as the dependence upon activated JNK for growth inhibition. However, the two compounds have significant differences in their ability to degrade the PML/RARa fusion oncoprotein, their response to concomitant antioxidant treatment, and the levels of intracellular arsenic, that accumulate upon exposure. The degradation of the PML/RARa oncoprotein, unique to APL, has been proposed to be involved in As 2 O 3 -induced differentiation of NB4 cells.
1,2 In contrast, As 2 O 3 -induced apoptosis is likely independent of PML/RARa degradation. 13 Unlike As 2 O 3 , we found that concentrations of darinaparsin that induce apoptosis do not cause PML/RARa degradation and cannot restructure nuclear bodies in NB4 cells. Although this might be a surprising result, several other arsenic-containing compounds fail to degrade PML/RARa. The organic arsenical, melarsoprol, commonly used to treat trypanosomiasis, does not degrade PML/RARa. 35 In addition, both mono-and di-methylated metabolites of arsenic do not degrade PML/RARa. 19 Darinaparsin contains dimethylarsenite, therefore, our results concur with those showing that biotransformation products of arsenic do not degrade PML/RARa and that induction of apoptosis is independent of its expression.
We and others have previously shown that two antioxidants, AA and trolox, become pro-oxidants when combined with As 2 O 3 and enhance As 2 O 3 -mediated cytotoxicity. Here, we present data that, although darinaparsin induces ROS, darinaparsin-induced apoptosis is substantially reduced by the concomitant addition of either AA or trolox. One possible explanation may be that As 2 O 3 and darinaparsin differ in the amount of ROS produced and/or the subcellular compartment in which they are produced. Data from Figure 3d support this by demonstrating that both compounds produce mitochondrial ROS, but only darinaparsin produced significant amount of total O 2 À . Both the mitochondrial transport chain and the nicotinamide adenine dinucleotide phosphate oxidase complex have been implicated in As 2 O 3 -generated ROS in varying model systems. 36, 37 The extent to which these ROS-generating systems contribute to darinaparsin-induced cytotoxicity is currently under investigation.
The magnitude of As 2 O 3 -induced cytotoxicity has been inversely correlated with the intracellular GSH pool. Cells are protected from darinaparsin-induced apoptosis by NAC, a precursor of GSH synthesis, similar to As 2 O 3 . This confirms data showing that exogenous GSH, cysteine and NAC prevented darinaparsin-induced cytotoxicity in a rat liver cell line. 38 However, depletion of GSH by BSO had no effect on darinaparsin-induced apoptosis, whereas it significantly enhanced As 2 O 3 -induced apoptosis. Although surprising, it has been previously shown that BSO does not enhance darinaparsin-induced cell death in hepatocytes and in cultured BALB/c 3T3 cells. 12, 39 We hypothesize that darinaparsin could induce apoptosis using mechanisms of action different than other forms of arsenic studied.
In order to explain the increased efficacy of darinaparsin, we compared the level of intracellular arsenic after exposure to either As 2 O 3 or darinaparsin in NB4 cells or the As 2 O 3 -resistant AR2 cells. Cells treated with darinaparsin accumulated the same amount of intracellular arsenic as those treated with As 2 O 3 , even though the darinaparsin supplies half the amount of elemental arsenic. This could indicate that darinaparsin is more efficiently transported into the cells and is supported by other studies demonstrating that dimethylated As III is more cell permeable when compared to inorganic As III . 40 A methylated form of arsenic linked to a GSH moiety was significantly more toxic than its counterpart devoid of a GSH moiety, because the GSH-containing form of arsenic accumulated faster in cells. 39 Darinaparsin may also be less efficiently exported from the cell, resulting in an increased intracellular arsenic concentration. This hypothesis is supported by data comparing As 2 O 3 -sensitive (NB4) or resistant (AR2) cells, where darinaparsin accumulates similarly in both NB4 and AR2 cells. When treated with As 2 O 3 , AR2 cells have about 50% of the intracellular arsenic as compared to NB4 cells. This may be due the B8-fold increase in ABCC1/MRP1 exporter expression in AR2 (Figure 7a ). This transporter has been linked to arsenic resistance by increasing export. Our results suggest that darinaparsin is not efficiently exported by ABCC1, because NB4 and AR2 have equivalent amounts of intracellular arsenic after darinaparsin exposure. In addition, an ABCC1 inhibitor effectively sensitized AR2 cells to As 2 O 3 , but had no effect of darinaparsin-induced growth inhibition (Figure 7) .
It is tempting to contribute the enhanced efficacy of darinaparsin to the dimethylated arsenite component in light of studies showing the methylated biotransformation products of arsenite to be more toxic than the parent compound. 19 However, we and others have data showing that the monomethylated arsenite metabolite induces cell death in NB4 cells to an equal or greater degree than As 2 O 3 , whereas dimethylarsenite did not significantly alter the growth of these cells 19 (and unpublished observations). Our data support the notion that the form under which arsenic is administrated can regulate its accumulation and the induction of apoptotic death in malignant cells and thus potentially enhance its therapeutic index in the clinic.
